|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2002-8-29
|
|
pubmed:abstractText |
Patients with end-stage renal disease are subject to a broad range of thrombotic complications. Low molecular weight heparins (LMWHs) are effective antithrombotic agents; however, they are cleared largely by renal mechanisms, raising uncertainty about their use in renally impaired patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1523-6838
|
|
pubmed:author |
pubmed-author:AssaidChristopher ACA,
pubmed-author:BarrettJeffrey SJS,
pubmed-author:CoxDonna SDS,
pubmed-author:FosslerMichael JMJ,
pubmed-author:HainerJames WJW,
pubmed-author:HuaTsushung ATA,
pubmed-author:PittengerAmy LAL,
pubmed-author:SherrardDonald JDJ,
pubmed-author:StephensonCarol ACA,
pubmed-author:SwanSuzanne KSK,
pubmed-author:WilliamsRobert MRM
|
|
pubmed:copyrightInfo |
Copyright 2002 by the National Kidney Foundation, Inc.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
40
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
531-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12200805-Adolescent,
pubmed-meshheading:12200805-Adult,
pubmed-meshheading:12200805-Aged,
pubmed-meshheading:12200805-Antithrombin III,
pubmed-meshheading:12200805-Biological Markers,
pubmed-meshheading:12200805-Blood Coagulation,
pubmed-meshheading:12200805-Cross-Over Studies,
pubmed-meshheading:12200805-Dizziness,
pubmed-meshheading:12200805-Fibrinolytic Agents,
pubmed-meshheading:12200805-Headache,
pubmed-meshheading:12200805-Hemorrhage,
pubmed-meshheading:12200805-Heparin, Low-Molecular-Weight,
pubmed-meshheading:12200805-Humans,
pubmed-meshheading:12200805-Injections, Intravenous,
pubmed-meshheading:12200805-Injections, Subcutaneous,
pubmed-meshheading:12200805-Kidney Failure, Chronic,
pubmed-meshheading:12200805-Middle Aged,
pubmed-meshheading:12200805-Nausea,
pubmed-meshheading:12200805-Prospective Studies,
pubmed-meshheading:12200805-Thrombin,
pubmed-meshheading:12200805-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.
|
|
pubmed:affiliation |
Bristol-Myers Squibb Pharma Company, Wilmington, DE, USA. james.hainer@astrazeneca.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
